Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02879929
Other study ID # DyNaChron
Secondary ID
Status Completed
Phase N/A
First received August 19, 2016
Last updated August 13, 2017
Start date October 2005
Est. completion date December 2006

Study information

Verified date August 2017
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Nasal symptoms are the main elements that lead to a therapeutic decision and allow for evaluating treatment effects or natural evolution. Despite availability of several questionnaires with good measurement qualities, no systematic assessment takes into account the specific physical and psychosocial consequences of each of the six main nasal symptoms, independently of the disease. The study proposed to measure these symptoms with the use of a selfreport questionnaire and to test the validity of the questionnaire in a large representative sample of patients attending outpatient rhinologic clinics.


Description:

The study was conducted in two parts: (1) expert-based development and testing of the face validity of a questionnaire in French; and (2) validity testing, including construct validity by factor analysis, reproducibility by intraclass correlation coefficient (ICC) and Bland and Altman plots, and sensitivity to change by standardized response means, on a large sample of patients in a prospective multicenter study. DyNaChron, a questionnaire with 78 items divided into six domains and exploring both the physical and psychosocial repercussions of CND, was developed. In total, 759 patients completed the questionnaire at a first visit to a clinic, and 539 again 19.5 days later, on average.


Recruitment information / eligibility

Status Completed
Enrollment 759
Est. completion date December 2006
Est. primary completion date December 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:Patients had to

- be older than 18 years

- have nasal or sinus dysfunction for more than 3 months

- be able to understand and read theFrench language.

Exclusion Criteria:

- nasal or sinus tumor or Rendu-Osler disease,

- patients were under immediate post-operative care

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

References & Publications (1)

Kacha S, Guillemin F, Jankowski R. Development and validity of the DyNaChron questionnaire for chronic nasal dysfunction. Eur Arch Otorhinolaryngol. 2012 Jan;269(1):143-53. doi: 10.1007/s00405-011-1690-z. Epub 2011 Jul 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Development of the DyNaChron questionnaire for chronic nasal dysfunction to develop a self-report questionnaire to assess nose and sinus functional symptoms together with their consequences for physical and psychosocial areas 6 months
Secondary Validation of the DyNaChron questionnaire for chronic nasal dysfunction to test the validity of the new instrument developped in a large representative sample of patients attending outpatient rhinology clinics 10 months
See also
  Status Clinical Trial Phase
Completed NCT02360072 - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed NCT02340130 - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma Phase 2
Completed NCT01118312 - Study of Asthma and Nasal Steroids Phase 4
Completed NCT00762567 - Phenylephrine Pediatric Pharmacokinetic Study Phase 1
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Completed NCT00279916 - Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays Phase 3
Completed NCT00963573 - Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428) Phase 4
Completed NCT00524836 - Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis Phase 3
Completed NCT00521131 - Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites Phase 4
Completed NCT04132570 - A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution Phase 4
Completed NCT02784262 - Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis Phase 2
Terminated NCT02630472 - Topical Irrigation Therapy for CRS Phase 1/Phase 2
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Completed NCT02279706 - Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test N/A
Completed NCT01971086 - Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary N/A
Completed NCT01771120 - Control and Burden of Asthma and Rhinitis N/A
Completed NCT01469234 - A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Phase 4
Withdrawn NCT01177852 - Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis Phase 3
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT02272101 - Rhinitis in the Elderly: The Role of Vitamin D Phase 3